# Haduvio

Type: Product

Source: Healthcare Intelligence Brief — https://gethealthbrief.com/entity/haduvio
Canonical HTML page: https://gethealthbrief.com/entity/haduvio

## Timeline

- **2026-03-18**: Q4 Earnings Call — Management details strategic advances and future clinical roadmap.
- **2026 (projected)**: Data Readout — Anticipated Phase 2b/3 data for Haduvio in chronic cough indications.
- **2025-12-31**: Fiscal Year End — Trevi concludes 2025 with key clinical milestones met for IPF chronic cough.
- **2025-10-15**: Q4 Strategic Pivot — Trevi refocuses resources on Haduvio's late-stage respiratory trials.

## Recent coverage (1 stories)

### Trevi Therapeutics Advances Chronic Cough Pipeline Amid Q4 Strategic Pivot
2026-03-18 04:09:28 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Trevi Therapeutics reported significant strategic progress in its Q4 2025 earnings, focusing on the clinical development of Haduvio for chronic cough in IPF. While the company achieves key R&D milestones, the broader biotech sector continues to navigate a complex financial landscape characterized by high capital costs and strategic realignments.
Full story: https://gethealthbrief.com/story/trevi-therapeutics-q4-2025-earnings-analysis

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://gethealthbrief.com/guides/methodology for the full editorial methodology.